Cellectar Biosciences completes 1-for-30 reverse stock split effective June 24, 2025

Cellectar Biosciences, Inc.

Reverse split ratio set at 1-for-30 for common stock, par value $0.00001.
Amendment to Second Amended and Restated Certificate of Incorporation filed.
Fractional shares not issued; aggregate fractions sold by transfer agent and net proceeds distributed pro rata.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cellectar Biosciences, Inc.: Effected a one-for-thirty reverse stock split by amending the Second Amended and Restated Certificate of Incorporation (effective 2025-06-24).

Change: charter amendment
Effective: 2025-06-24

Exact text from the filing

On June 24, 2025, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), effected a one-for-thirty reverse stock split of the Company’s common stock, par value $0.00001 (the “Reverse Split”) by amending its Second Amended and Restated Certificate of Incorporation (the “Amendment”).

View on SEC.gov

Browse all governance changes →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-062639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.